A Phase 1 interventional study of HRS-9813 Capsule and HRS-9813 Tablet in Pulmonary Fibrosis, sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 45 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-08.
Sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd (part of Jiangsu HengRui Medicine Co., Ltd.) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 40 studies in Pulmonary Fibrosis with a site in China — 14 open to participants now, 18 under way, 4 of them phase 3. Pulmonary Fibrosis · China.
Among the 40 studies in Pulmonary Fibrosis with a site in China, this one is the 28th largest by enrollment of the 30 interventional ones that give a count, is one of 5 that started in 2025, is one of 9 in phase 1, and was the 33rd registered.
342 studies on the registry are indexed under Pulmonary Fibrosis; 98 are open to participants now.
Browse Pulmonary Fibrosis studies →14 of the 40 studies in Pulmonary Fibrosis with a site in China are open now. Recruiting first, the newest first:
Peking Union Medical College Hospital · Sites in China
Ages 18–85 · Healthy volunteers
Ming Zhong · Sites in China
Ages 18–89
Zuojun Xu · Sites in China
ChromX Health · Sites in China
Ages 18–100 · Healthy volunteers
Second Affiliated Hospital, School of Medicine, Zhejiang University · Sites in China
Ages 18–80
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 71 Pulmonary Fibrosis studies recruiting now, 41 (58%) set no upper age limit and 4 (6%) stop at 75 or younger; 8 take children under 18; 12 take healthy volunteers.
This study: 18 Years to 45 Years · all sexes · healthy volunteers too.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
40 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 10 · Phase 2 10 · Phase 3 8
First in 2007; this study’s year is marked. 5 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 12 is below the median of 59 across 212 interventional studies indexed under Pulmonary Fibrosis.
Median enrollment 146 across the 30 interventional studies, 200 across the 10 observational. Of the 18 that completed or were terminated, 9 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
20 of 40 have an industry lead sponsor. The 10 most frequent:
This study is registered under Guangdong Hengrui Pharmaceutical Co., Ltd, one of the names counted as Jiangsu HengRui Medicine Co., Ltd.. Under that name alone:
Guangdong Hengrui Pharmaceutical Co., Ltd is the lead sponsor of 59 studies on the registry; 25 are open to participants now.
Jiangsu HengRui Medicine Co., Ltd. has 2 studies filed under Pulmonary Fibrosis — fewer than ten, so there is no comparison to draw.
5 of the studies in Pulmonary Fibrosis with a site in China that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06125327Phase 3Guangzhou JOYO Pharma Co., LtdSC1011 Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) | 2026-12-31 |
| NCT05139719Sunshine Lake Pharma Co., Ltd.A Study to Explore the Therapeutic Effect of HEC585 on Delaying Forced Vital Capacity (FVC) Decline and Tolerance in Progressive Fibrosing Interstitial Lung Disease (PF-ILD) Patients | 2026-12 |
| NCT06528418ChromX HealthIdentification of Multiple Pulmonary Diseases Using Volatile Organic Compounds Biomarkers in Human Exhaled Breath | 2026-12-30 |
| NCT07396467The First Affiliated Hospital with Nanjing Medical UniversityClinical Outcomes and Immunotherapy in Lung Cancer With Pulmonary Fibrosis | 2026-12-31 |
| NCT07464132Peking Union Medical College HospitalApplication of [68Ga]Ga-NI-FAPI-04 PET/CT Imaging in Fibroblast Activation Protein Related Diseases | 2027-02-17 |
Add all 5 to your calendar (.ics) → With an account.
Among the 40 studies in Pulmonary Fibrosis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
This is a phase Ⅰ study to evaluate the relative bioavailability of HRS-9813 capsule and tablet in healthy subjects and the effect of food on the pharmacokinetics of HRS-9813 capsule.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: HRS-9813 Capsule
Drug: HRS-9813 Tablet
HRS-9813 capsule.
HRS-9813 tablet.
Maximum observed concentration of HRS-9813 capsule (Cmax)
Time frame: Day 1-Day 23.
Maximum observed concentration of HRS-9813 tablet (Cmax)
Time frame: Day 1-Day 23.
Area under the concentration-time curve from time 0 to infinity of HRS-9813 tablet (AUC0-inf)
Time frame: Day 1-Day 23.
Area under the concentration-time curve from time 0 to infinity of HRS-9813 capsule (AUC0-inf)
Time frame: Day 1-Day 23.
Adverse events (AEs)
Time frame: Day 1-Day 23.
Time to Cmax of HRS-9813 capsule (Tmax).
Time frame: Day 1-Day 23.
Time to Cmax of HRS-9813 tablet (Tmax).
Time frame: Day 1-Day 23.
Plan to share: Undecided
No publications or documents are linked to this record.
Ran from May 2025 to primary completion in Jun 2025, 0 months.
Of 20 phase 1 interventional studies under Pulmonary Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 3 and three quarters within 55. This study's 0 months is below that.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: HRS-9813
Guangdong Hengrui Pharmaceutical Co., Ltd →